Loading organizations...
Loading organizations...

Robotic human cell manufacturing
Mytos builds robots for manufacturing human cells. Operators input stem cells, and our platform turns them into specific cells such as neurons and heart cells over multiple weeks.
Last year, patients were cured of Parkinson’s, vision loss, and Type 1 diabetes using stem-cell derived cells. We need 1000x the global capacity to produce these cells, and treat millions of patients. But today these Regenerative Medicines are produced by hand, meaning they’re too expensive and don’t scale.
Mytos has fully automated production of these cells, making it scalable. We have our first manufacturing deal - neurons for treating Parkinson’s - and we’re in conversations with majority of the other top players.
Mytos has raised $21.0M across 2 funding rounds.
Key people at Mytos.
Mytos was founded in 2016 by Ali Afshar (Founder/CEO) and Ignacio Willats (Founder).
Mytos has raised $21.0M in total across 2 funding rounds.
Mytos is a pioneering company that builds robotic systems to automate the manufacturing of human cells, specifically turning stem cells into specialized cells like neurons and heart cells. This automation addresses a critical bottleneck in regenerative medicine and cell therapy development, where manual cell production is costly, slow, and inconsistent. By fully automating this process, Mytos enables scalable, low-cost production of high-quality cells, supporting treatments for diseases such as Parkinson’s, vision loss, and Type 1 diabetes. Their platform serves biotech companies and pharmaceutical firms by streamlining cell manufacturing, reducing human error, and accelerating drug development timelines. Mytos has secured manufacturing deals with multiple clinical-stage biotechs and is expanding its capacity through automated manufacturing sites, aiming to treat millions of patients globally[1][2][3][4][5][6].
Founded in 2018, Mytos was co-founded by Ali Afshar, a scientist-engineer hybrid with expertise in physics, chemistry, hardware, and software, and Ignacio Willats. The idea emerged from the need to overcome the limitations of manual cell culture in regenerative medicine, which is labor-intensive and difficult to scale. Early traction came from automating stem cell-derived cell production for major US pharmaceutical companies and refining their iDEM automation technology through multiple iterations. This evolution enabled Mytos to transition from research-focused automation to operating fully automated manufacturing sites, positioning the company as a key player in scalable regenerative medicine production[1][2][3][8].
Mytos rides the wave of regenerative medicine and cell therapy maturation, where scalable, cost-effective manufacturing is a critical unmet need. The timing is crucial as the industry shifts from manual, artisanal cell production to automated, GMP-compliant processes to meet growing clinical and commercial demand. Market forces such as increasing investment in cell therapies, regulatory support for advanced therapies, and the need for reproducible manufacturing standards favor Mytos’ approach. By enabling scalable production, Mytos accelerates the translation of regenerative medicines from clinical trials to widespread patient access, influencing the broader biotech ecosystem by setting new manufacturing benchmarks[1][2][5][6].
Looking ahead, Mytos is poised to expand its global manufacturing footprint with multiple automated sites, increasing capacity to deliver tens of thousands of doses annually. Trends shaping their journey include continued growth in regenerative medicine, advances in automation and digital monitoring, and increasing demand for cell therapies across diverse indications. As Mytos scales, its influence will likely deepen, potentially becoming the backbone of regenerative medicine manufacturing and enabling millions of patients to access transformative therapies at lower cost. Their success will hinge on maintaining technological leadership, expanding partnerships, and navigating regulatory pathways for commercial-scale cell therapy production[5][6].
Key people at Mytos.
Mytos was founded in 2016 by Ali Afshar (Founder/CEO) and Ignacio Willats (Founder).
Mytos has raised $21.0M in total across 2 funding rounds.
Mytos's investors include Jonathan Choi, IQ Capital, Wing Venture Capital, AiSprouts VC, Hoxton Ventures, Jude Gomila Rolling Fund, Jonathan Golden, Quiet Capital, Gil Penchina, Unpopular Ventures, Winklevoss Capital.
Mytos has raised $21.0M across 2 funding rounds. Most recently, it raised $19.0M Series A in November 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 30, 2023 | $19.0M Series A | Jonathan Choi | IQ Capital, Wing Venture Capital |
| Aug 1, 2018 | $2.0M Seed | AiSprouts VC, Hoxton Ventures, Jude Gomila Rolling Fund, Jonathan Golden, Quiet Capital, Gil Penchina, Unpopular Ventures, Winklevoss Capital |